Education

Ph.D. in Biotechnology, Department of Biotechnology, College of Engineering, Yonsei University, Seoul, Korea, 2002

Current position

Professor, Department of Pharmacology, School of Medicine, Konkuk University, Kwangjin-gu, Seoul, Korea

Publications

1. Kim, K. H.*, Chang, H. Y., Park, J. Y., Park, E. S., Park, Y. K., Han, K. H. and Ahn, S. H. (2014). Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers. Clin Mol Hepatol 20(3): 251-260.
   
2. Park, E. S., Lee, J. H., Hong, J. H., Park, Y. K., Lee, J. W., Lee, W. J., Lee, J. W., Kim, K. P. and Kim, K. H.* (2014). Phosphatidylcholine alteration identified using MALDI imaging MS in HBV-infected mouse livers and virus-mediated regeneration defects. PLoS One 9(8): e103955. (IF 3.73)
   
3. Shin, G. C., Ahn, S. H., Choi, H. S., Kim, J., Park, E. S., Kim, D. H. and Kim, K. H.* (2014). Hepatocystin contributes to interferon-mediated antiviral response to hepatitis B virus by regulating hepatocyte nuclear factor 4alpha. Biochim Biophys Acta 1842(9): 1648-1657. (IF 5.387)
   
4. Ahn, S. H., Park, Y. K., Park, E. S., Kim, J. H., Kim, D. H., Lim, K. H., Jang, M. S., Choe, W. H., Ko, S. Y., Sung, I. K., Kwon, S. Y. and Kim, K. H.* (2014). The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol 88(12): 6805-6818. (IF 5.343)
   
5. Kim, J. H., Park, Y. K., Park, E. S. and Kim, K. H.* (2014). Molecular diagnosis and treatment of drug-resistant hepatitis B virus. World J Gastroenterol 20(19): 5708-5720. (IF 2.547)
   
6. Kim, B. K., Choi, S. H., Ahn, S. H., Chung, A. R., Park, Y. K., Han, K. H., Kim, S., Kim, H. S., Park, J. H., Kim, K. S., Lee, H. S., Cho, Y. S., Kim, K. H. and Ahn, S. H. (2014). Pre-S mutations of hepatitis B virus affect genome replication and expression of surface antigens. J Gastroen Hepatol 29(4): 843-850. (IF 3.627)
   
7. Park, E. S. and Kim, K. H.* (2013). Role of the hepatitis B virus X protein in viral pathogenesis. Bio Design 1(1): 20-25.
   
8. Choi, S. I., Kwon, S., Son, A., Jeong, H., Kim, K. H. and Seong, B. L. (2013). Protein folding in vivo revisited. Curr Protein Pept Sci 14(8): 721-733. (IF 2.326)
   
9. Kim, D. H., Ahn, S.H., Kim, K. H.* (2013). Hepatitis B virus and antiviral drug resistance TiBMB). Trends in Biochemistry and Molecular Biology 35-42.
   
10. Jang, Y. H., Byun, Y. H., Lee, K. H., Park, E. S., Lee, Y. H., Lee, Y. J., Lee, J., Kim, K. H. and Seong, B. L. (2013). Host defense mechanism-based rational design of live vaccine. PLoS One 8(10): e75043. (IF 4.092)
    
11. Park, E. S., Park, Y. K., Shin, C. Y., Park, S. H., Ahn, S. H., Kim, D. H., Lim, K. H., Kwon, S. Y., Kim, K. P., Yang, S. I., Seong, B. L. and Kim, K. H.* (2013). Hepatitis B virus inhibits liver regeneration via epigenetic regulation of urokinase-type plasminogen activator. Hepatology 58(2): 762-776. (IF 12.003)
    
12. Shin, G. C., Ahn, S. H., Choi, H. S., Lim, K. H., Choi do, Y., Kim, K. P. and Kim, K. H.* (2013). Hepatocystin/80K-H inhibits replication of hepatitis B virus through interaction with HBx protein in hepatoma cell. Biochim Biophys Acta 1832(10): 1569-1581. (IF 5.387)
    
13. Lim, K. H., Choi, H. S., Park, Y. K., Park, E. S., Shin, G. C., Kim, D. H., Ahn, S. H. and Kim, K. H.* (2013). HBx-induced NF-kappaB signaling in liver cells is potentially mediated by the ternary complex of HBx with p22-FLIP and NEMO. PLoS One 8(3): e57331. (IF 4.092)
    
14. Jung, J. W., Bae, S. J., Kang, G. Y., Kim, K. H., Yeo, W. S., Park, S. H., Seol, J. H., Yi, E. C. and Kim, K. P. (2013). Analysis of the biochemical role of Lys-11 in polyubiquitin chain formation using quantitative mass spectrometry. Rapid Commun Mass Spectrom 27(2): 339-346. (IF 2.79)
    
15. Ko, S. Y., Kim, B. K., Kwon, S. Y., Kim, K. H., Kim, J. H., Choe, W. H. and Lee, C. H. (2012). Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. World J Gastroenterol 18(44): 6437-6446; discussion p 6445. (IF 2.471)
    
16. Ko, S. Y., Choe, W. H., Kwon, S. Y., Kim, J. H., Seo, J. W., Kim, K. H. and Lee, C. H. (2012). Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy. Scand J Gastroenterol 47(11): 1362-1367. (IF 2.019)
    
17. Shanta, S. R., Kim, T. Y., Hong, J. H., Lee, J. H., Shin, C. Y., Kim, K. H., Kim, Y. H., Kim, S. K. and Kim, K. P. (2012). A new combination MALDI matrix for small molecule analysis: application to imaging mass spectrometry for drugs and metabolites. Analyst 137(24): 5757-5762. (IF 4.23)
    
18. Shanta, S. R., Choi, C. S., Lee, J. H., Shin, C. Y., Kim, Y. J., Kim, K. H. and Kim, K. P. (2012). Global changes in phospholipids identified by MALDI MS in rats with focal cerebral ischemia. J Lipid Res 53(9): 1823-1831. (IF 5.559)
    
19. Lim, K. H., Kim, K. H.*, Choi, S. I., Park, E. S., Park, S. H., Ryu, K., Park, Y. K., Kwon, S. Y., Yang, S. I., Lee, H. C., Sung, I. K. and Seong, B. L.* (2011). RPS3a over-expressed in HBV-associated hepatocellular carcinoma enhances the HBx-induced NF-kappaB signaling via its novel chaperoning function. PLoS One 6(8): e22258. (IF 4.411)
    
20. Kim, J. K., Lee, J. R., Kang, J. W., Lee, S. J., Shin, G. C., Yeo, W. S., Kim, K. H., Park, H. S. and Kim, K. P. (2011). Selective enrichment and mass spectrometric identification of nitrated peptides using fluorinated carbon tags. Anal Chem 83(1): 157-163. (IF 5.214)
    
21. Kim, K. H.* (2010). Epigenetics and cancer. The Konkuk Journal of Medical Science 14(2):75-82. Review.
    
22. Lee, J., Sung, I., Kim, J., Lee, S., Hong, S., Park, H., Shim, C., Jin, C., Han, H. and Kim, K.* (2010). Impact of Clarithromycin resistance on the outcome of standard triple Helocibacter pylori eradication therapy. Korean J Helicobacter Up Gastrointest Res 10: 14-20.
    
23. Kim, N. D., Park, E. S., Kim, Y. H., Moon, S. K., Lee, S. S., Ahn, S. K., Yu, D. Y., No, K. T. and Kim, K. H.* (2010). Structure-based virtual screening of novel tubulin inhibitors and their characterization as anti-mitotic agents. Bioorg Med Chem 18(19): 7092-7100. (IF 3.075)
    
24. Kim, K. H.*, Kim, N. D. and Seong, B. L. (2010). Discovery and development of anti-HBV agents and their resistance. Molecules 15(9): 5878-5908. (IF 2.386)
    
25. Kim, K. H.* (2010). Pro-apoptotic function of hepatitis B virus X protein. Korean J Hepatol 16(2): 112-122.
    
26. Kwon, S. Y., Park, Y. K., Ahn, S. H., Cho, E. S., Choe, W. H., Lee, C. H., Kim, B. K., Ko, S. Y., Choi, H. S., Park, E. S., Shin, G. C. and Kim, K. H.* (2010). Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol 84(9): 4494-4503. (IF 5.343)
    
27. Kim, K. H., Kim, N. D. and Seong, B. L. (2010). Pharmacophore-based virtual screening: a review of recent applications. Expert Opin Drug Discov 5(3): 205-222. (IF 2.116).
    
28. Ryu, K., Kim, K. H., Yoo, S. Y., Lee, E. Y., Lim, K. H., Min, M. K., Kim, H., Choi, S. I. and Seong, B. L. (2010). Production and characterization of active hepatitis C virus RNA-dependent RNA polymerase. Protein Expr Purif 71(2): 147-152. (IF 1.847)
    
29. Choe, W. H., Hong, S. P., Kim, B. K., Ko, S. Y., Jung, Y. K., Kim, J. H., Yeon, J. E., Byun, K. S., Kim, K. H., Ji, S. I., Kim, S. O., Lee, C. H. and Kwon, S. Y. (2009). Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther 14(7): 985-993. (IF 4.547)
    
30. Ryu, K., Kim, N. D., Choi, S. I., Han, C. K., Yoon, J. H., No, K. T., Kim, K. H.* and Seong, B. L.* (2009). Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Bioorg Med Chem 17(8): 2975-2982. (IF3.075) (*Corresponding authors)
    
31. Ko, S. Y., Kwon, S. Y., Choe, W. H., Kim, B. K., Kim, K. H. and Lee, C. H. (2009). Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study. Antivir Ther 14(4): 585-590. (IF 4.547)
    
32. Ito, K., Kim, K. H., Lok, A. S. and Tong, S. (2009). Characterization of genotype-specific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme. J Virol 83(8): 3507-3517. (IF 5.343)
    
33. Choe, W. H., Kwon, S. Y., Kim, B. K., Ko, S. Y., Yeon, J. E., Byun, K. S., Kim, G. H. and Lee, C. H. (2008). Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int 28(6): 814-820. (IF 2.559)
    
34. Ryu, K., Kim, C. W., Kim, B. H., Han, K. S., Kim, K. H., Choi, S. I. and Seong, B. L. (2008). Assessment of substrate-stabilizing factors for DnaK on the folding of aggregation-prone proteins. Biochem Biophys Res Commun 373(1): 74-79. (IF 2.855)
    
35. Choi, S. I., Han, K. S., Kim, C. W., Ryu, K. S., Kim, B. H., Kim, K. H., Kim, S. I., Kang, T. H., Shin, H. C., Lim, K. H., Kim, H. K., Hyun, J. M. and Seong, B. L. (2008). Protein solubility and folding enhancement by interaction with RNA. PLoS One 3(7): e2677. (IF 4.411)
    
36. Lee, S. J.*, Kim, K. H.*, Park, J. S., Jung, J. W., Kim, Y. H., Kim, S. K., Kim, W. S., Goh, H. G., Kim, S. H., Yoo, J. S., Kim, D. W. and Kim, K. P. (2007). Comparative analysis of cell surface proteins in chronic and acute leukemia cell lines. Biochem Biophys Res Commun 357(3): 620-626. (IF 2.855) (*Co-first authors)
    
37. Kim, K. H. (2008). HBx interference in pro- and anti-apoptotic pathways, In: Kobarg, J. (ed). The pleiotropic functions of the viral protein HBx in Hepatitis B virus infection and the development of liver cancer. Research Signpost 81-108.
    
38. Kim, C. W., Han, K. S., Ryu, K. S., Kim, B. H., Kim, K. H., Choi, S. I. and Seong, B. L. (2007). N-terminal domains of native multidomain proteins have the potential to assist de novo folding of their downstream domains in vivo by acting as solubility enhancers. Protein Sci 16(4): 635-643. (IF 3.462)
    
39. Shin, C. Y. and Kim, K. H. (2006). Polyadenylation-dependent translational control of new protein synthesis at activated synapse. Biomolecules & Therapeutics 14(2): 75-82. Review
    
40. Kim do, Y., Kim, K. H.*, Kim, N. D., Lee, K. Y., Han, C. K., Yoon, J. H., Moon, S. K., Lee, S. S. and Seong, B. L.* (2006). Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem 49(19): 5664-5670.(IF 5.115)
    
41. Guarnieri, M., Kim, K. H., Bang, G., Li, J., Zhou, Y., Tang, X., Wands, J. and Tong, S. (2006). Point mutations upstream of hepatitis B virus core gene affect DNA replication at the step of core protein expression. J Virol 80(2): 587-595. (IF 5.343)
    
42. Tong, S., Kim, K. H., Chante, C., Wands, J. and Li, J. (2005). Hepatitis B Virus e antigen variants. Int J Med Sci 2(1): 2-7. Review
    
43. Bang, G., Kim, K. H., Guarnieri, M., Zoulim, F., Kawai, S., Li, J., Wands, J. and Tong, S. (2005). Effect of mutating the two cysteines required for HBe antigenicity on hepatitis B virus DNA replication and virion secretion. Virology 332(1): 216-224. (IF 3.765)
    
44. Khan, N., Guarnieri, M., Ahn, S. H., Li, J., Zhou, Y., Bang, G., Kim, K. H., Wands, J. R. and Tong, S. (2004). Modulation of hepatitis B virus secretion by naturally occurring mutations in the S gene. J Virol 78(7): 3262-3270. (IF 5.398)
    
45. Kim, K. H., Ahn, S. H., Chung, H. Y., Paik, Y. H., Lee, K. S., Kim, Y. S., Chon, C. Y., Moon, Y. M. and Han, K. H. (2004). Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J Gastroenterol Hepatol 19(8): 847-853. (IF3.325) *Comment on: J Gastroenterol Hepatol. 2004 Aug; 19(8):847-853.
    
46. Kim, K. H., Lee, K. H., Chang, H. Y., Ahn, S. H., Tong, S., Yoon, Y. J., Seong, B. L., Kim, S. I. and Han, K. H. (2003). Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. J Med Virol 71(3): 367-375. (IF 2.739)
    
47. Kim, K. H. and Seong, B. L. (2003). Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. EMBO J 22(9): 2104-2116. (IF 12.459)
    
48. Han, K. H., Kim, K. H. and Chang, H. Y. (2002). Immunogenetics of hepatitis B virus infection. J Gastroenterol Hepatol 17 Suppl 3: S329-332. (IF 3.325)
    
49. Kim, K.-H. and Seong, B. L. (2001). Peptide amidation: Production of peptide hormones in vivo and in vitro. Biotechnology and Bioprocess Engineering 6(4): 244-251.Review. (IF 1.653)